KRAS mutations result in the production of an abnormal KRAS protein that is permanently active. This leads to constant signaling for cell growth and division, bypassing the normal regulatory mechanisms. Consequently, cells proliferate uncontrollably, which is a hallmark of tumorigenesis. These mutations are particularly common in cancers such as pancreatic, colorectal, and lung cancer.
